logo
It's much faster to get hip or knee replacements if there's a central waitlist: study

It's much faster to get hip or knee replacements if there's a central waitlist: study

CBC20-05-2025
Canadians who need a hip or knee replacement could get the surgery more quickly — without adding to health-care budgets or opening more operating rooms — if central waitlists were created, the author of a new study says.
The findings, published in Tuesday's issue of the Canadian Medical Association Journal, suggest it's significantly faster to add patients to a central list where they can see any surgeon in their area, compared to each surgeon having their own waitlists.
Right now in Ontario, a primary care provider, such as your family doctor, refers you to a surgeon or physiotherapist to decide whether surgery is needed. If it is, you'll be put on one surgeon's waiting list, which could be long or short.
Often, it's a long wait — in Canada, only two-thirds of patients receive their hip replacement within the 26-week recommended standard, according to data from the Canadian Institute for Health Information. For knee replacements, only 59 per cent are done within that time.
So that's prompted some provinces to experiment with how they assign surgery patients to waitlists, with the goal of shortening overall wait times.
For the study, Dr. David Urbach, head of the surgery department at Women's College Hospital in Toronto, and his team compared three models based on data collected from more than 17,000 patients across Ontario who were referred for hip or knee replacements in 2017.
The three models were:
Option 1: A family doctor refers you for assessment to a pool of surgeons or physiotherapists in the part of the province where you live. If you need surgery, you're assigned a surgeon and put on their waitlist.
Option 2: The family doctor refers you to a specific surgeon or physiotherapist to decide whether surgery is needed. If you need an operation, then you're put in a pool for the next available surgeon in the part of the province where you live.
Option 3: A combination of the first two: Your family doctor puts the request for assessment into a central pool — and, if you need surgery, you enter a second pool that includes all the qualified surgeons in your area and would see the next one available.
Currently, patients awaiting joint replacements are like customers at a grocery store, Urbach said in an interview — they're stuck in a line, even if another checkout opens up.
But the better option for surgery would be akin to going to the bank, where everybody moves through a common line and waits the shortest possible time.
WATCH | Hospital replaces hips in 35 minutes:
How a hospital is doing hip replacements in 35 minutes
1 year ago
Duration 4:52
Toronto's Humber River Hospital has started using a new model to get more hip replacement patients through the operating room. CBC's Christine Birak breaks down how hyper-throughput surgeries work and why the hospital says it's the type of innovation provinces should invest in.
When it comes to wait times, Urbach said the study found that random factors can crop up and slow down one surgeon — like one having an already long wait list and limited operating room time in a more rural area.
Shorter waits with new system
Priority for joint replacement surgery also depends on criteria like the degree of pain and disability and the risk of a worse outcome with a delay in surgery.
In Ontario, the goal is for a patient to wait no longer than six months for a consultation, with the maximum wait for the surgery itself being another six months, the researchers said.
For top priority cases, 90 days is the target wait time for those on a single surgeon's list, while the study found that comparable patients in the regional pool made it through in 84 days.
In the study, Option 3 — where there was a central intake for consultation and for surgery — nearly halved wait times for the vast majority of patients in all regions, ranging from 111 fewer days in Toronto (from 257 to 146 days) to 281 days in Ontario West (from 536 to 255 days).
Much of the wait time for joint replacements was for the surgery itself and not the consultation, the researchers found.
"Unless you introduce a team-based model of care, you just have to wait until a spot opens up and that could be very long," Urbach said. "That could be a year, year-and-a-half or longer."
Getting surgeons to buy in
Canadians may have heard of team-based primary care, where patients have access to a well-connected interprofessional team such as family doctors, nurse practitioners, social workers and dietitians.
Similarly, in team-based surgical care, a group of surgeons takes the next patient in order of priority, even if a patient's particular surgeon has a very long list, Urbach said.
Asked what kind of reaction surgeons have given to team-based surgical care so far, Urbach said many are skeptical about moving away from keeping their own list of patients.
"They're concerned that they'll lose their source of referrals," Urbach said.
Dr. Olufemi Ayeni, president of the Canadian Orthopaedic Association and an orthopedic surgeon at McMaster, said he sees that view dissipating among those in the profession.
"I think there will be some openness and there's definitely been a culture shift within orthopedics," Ayeni said. "We don't like hearing about patients who are suffering, needing pain medications. It feeds into other concerns [such as] opioid use."
The study's authors acknowledged that unless surgeons believe that team-based models of care are beneficial to them and do not threaten their autonomy or opportunities for income and professional advancement, "these models of care are unlikely to be viable in Canadian health systems in which physicians are highly independent."
Ayeni agreed, saying otherwise the response to team-based care among surgeons will be muted.
Mohamed Alarakhia, a family physician and managing director of the non-profit eHealth Centre for Excellence in Kitchener, Ont., uses e-referrals for specialists. Alarakhia said it has already reduced orthopedic wait times by 54 days.
Wait times across Canada
Using a central intake for both assessment and surgeries equalizes wait times overall among surgeons, Alarakhia said.
"We have examples in this province of where we've figured it out and across the country where they've done central intake," Alarakhia said, giving Quebec and Alberta as examples.
"I believe we can solve these problems if we get some of these things in place."
Health PEI said it's now adopting a centralized waitlist management system for surgical care, including hip and knee replacements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CVRx (CVRX) Q2 Revenue Jumps 15%
CVRx (CVRX) Q2 Revenue Jumps 15%

Globe and Mail

time9 minutes ago

  • Globe and Mail

CVRx (CVRX) Q2 Revenue Jumps 15%

Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025

Canada could lose its measles elimination designation by October: experts
Canada could lose its measles elimination designation by October: experts

National Post

time7 hours ago

  • National Post

Canada could lose its measles elimination designation by October: experts

This advertisement has not loaded yet, but your article continues below. Since the start of a new wave of measles cases last fall, Ontario had tallied 2,353 as of July 29, while Alberta's total number of cases as of Friday was 1,656 The province reported Friday that there are now 1,656 measles cases in Alberta. Measles cases across the country are being reported daily and, if the trend continues, Canada will likely lose its designation by October as a country that has eliminated measles. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Alberta currently has the second highest number of cases with 1,656 as of Friday afternoon, sitting behind Ontario, which is reporting 2,353 cases as of July 29. The situation in Canada has raised several red flags from experts and physicians with cases now exceeding those in the entire United States. Dr. Stephanie Smith, an infectious disease physician at the University of Alberta Hospital, said for a country to lose its designation as one that has eliminated measles, there has to be evidence of ongoing transmission within Canada for one year — not cases brought from elsewhere. Get a dash of perspective along with the trending news of the day in a very readable format. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again The first measles outbreak began in October 2024 in New Brunswick and, since then, has spread to 10 of 13 provinces and territories, according to the Government of Canada's measles dashboard. The only jurisdictions with no reported cases are Yukon, Nunavut, and Newfoundland and Labrador. 'I think that we will continue to have cases into the next several months. I think it's very unlikely that we won't lose our elimination status, which is really disappointing given this is something that is quite preventable,' Smith said. Smith said losing the designation doesn't mean anything specific, but is a metric to measure the general health of Canada's population and the health care system. Losing the designation would suggest Canada's public health systems are not where they should be compared to other high-income countries. Smith said the current number of cases is 'incredibly high' for measles. 'What is important to understand is that because measles is transmitted primarily by airborne route, the way that we have to manage that in the hospital is a little bit different, and it does make it quite challenging to manage patients in some health care settings,' she said. At Alberta Hospital Edmonton — a mental health hospital — she said there are no negative pressure rooms, which is where staff would put those who have measles. Smith said if a situation arose where an inpatient or patient has measles and needs the care provided by Alberta Hospital, they're unable to go there. Janna Shapiro, a postdoctoral fellow at the University of Toronto's Centre for Vaccine Preventable Diseases, said in Ontario, cases have slowed but are still present. Moving forward with future outbreaks of infectious diseases, she emphasized the need for better data on vaccination coverage across Canada and targeted outreach to address under-vaccination in certain communities. This advertisement has not loaded yet. This advertisement has not loaded yet, but your article continues below. 'I think the key here is prevention and starting programs before there's a problem,' Shapiro said. 'If you wait until there's an outbreak, it's really hard to get on top of it, especially with something as contagious as measles.' In a Thursday statement from Alberta's Ministry of Primary and Preventative Health Services to Postmedia, the ministry said the province takes the current measles situation seriously and is closely monitoring the outbreak. 'There are currently 16 active cases in Alberta — a number that has remained stable for several weeks,' the statement said. 'This stabilization is not simply the result of fewer people left to infect, as some have speculated, but reflects the impact of increased immunization rates and targeted public health interventions that are making a measurable difference.' According to the province, there have been more than 92,000 vaccinations administered between March 16 and July 26, a 57 per cent increase from the same time last year. It said in both the south and north zones, vaccinations rose by 122 per cent and 95 per cent. The province launched an immunization campaign in May, which it said will now expand through mid-August to keep momentum into the school year. 'Immunization remains our strongest defence. We continue to urge all Albertans to check their immunization records and ensure they and their children are up to date,' the statement said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store